We would like to extend our sincere thanks to our key supporters who granted funds towards our services, projects and activities this year, including the National Lottery Community Fund.
Other charitable trusts, foundations and organisations who kindly gave donations and grants in 2025 include Project Alive, the Sylvia Aitken Charitable Trust, David Lister Charitable Trust, the Blair Foundation, Himat Tanna Charitable Trust, the Florence Turner Trust, the Boshier-Hinton Foundation, The Arnold Clark Community Fund, The Reed Foundation, Bruce Wake Charitable Trust, Christopher and Elspeth Thomas Charitable Trust, the Charles and Elsie Sykes Trust, Baddiley Consolidated Charities, The Eveson Trust, the Walter Guinness Charitable Trust, Simon Gibson Charitable Trust, the Clover Trust, the Geoff and Fiona Squire Foundation, The W E Dunn Trust, Frazer Trust, the Annie Tranmer Charitable Trust, Enkalon Foundation, FSJ Charities, the Zochonis Charitable Trust, Sisters of the Holy Cross CIO, ShareGift, the Michael and Anna Wix Charitable Trust, the Strangward Trust, James Wood Bequest Fund, Medicash Foundation, the Ardwick Trust, the Bouttell Bequest, Oakdale Trust, James T Howat Charitable Trust, the Carrington Charitable Trust, Bowen Lodge Freemasons, The Hobson Charity, the Bobby & Steve Foundation, Enterprise Mobility™, the Constance Travis Charitable Trust, The Barbour Foundation and the Bartle Family Charitable Trust.
We were very grateful to receive financial contributions during 2025 from the following pharmaceutical companies towards various aspects of our patient support services and projects: Alexion, Amicus Therapeutics, BioMarin, Denali Therapeutics, JCR Pharmaceuticals, Orchard Therapeutics, REGENXBIO, Sanofi and Takeda UK have provided funding to MPS Society in support of 2025 patient projects but have had no input into content or output.
Chiesi Limited has provided an unrestricted financial grant to support the MPS Society’s frontline patient support services in 2025. Chiesi Limited has had no involvement in the development, delivery, or operational activities of these services.
Chiesi Farmaceutici S.p.A provided funding to support MPS Society’s patient projects during 2025; however, they were not involved in the development, content, or outcomes of these activities.
Ultragenyx have provided unrestricted funding to MPS Society in support of 2025 patient projects.